nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT2B7—Zidovudine—acquired immunodeficiency syndrome	0.07	0.0912	CbGbCtD
Dapagliflozin—CYP2A6—Nevirapine—acquired immunodeficiency syndrome	0.0547	0.0713	CbGbCtD
Dapagliflozin—CYP2A6—Zidovudine—acquired immunodeficiency syndrome	0.036	0.0468	CbGbCtD
Dapagliflozin—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0222	0.0289	CbGbCtD
Dapagliflozin—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0209	0.0272	CbGbCtD
Dapagliflozin—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0209	0.0272	CbGbCtD
Dapagliflozin—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.02	0.0261	CbGbCtD
Dapagliflozin—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0189	0.0246	CbGbCtD
Dapagliflozin—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0188	0.0245	CbGbCtD
Dapagliflozin—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0188	0.0245	CbGbCtD
Dapagliflozin—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0183	0.0238	CbGbCtD
Dapagliflozin—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0183	0.0238	CbGbCtD
Dapagliflozin—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0172	0.0224	CbGbCtD
Dapagliflozin—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0172	0.0224	CbGbCtD
Dapagliflozin—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.017	0.0222	CbGbCtD
Dapagliflozin—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.017	0.0222	CbGbCtD
Dapagliflozin—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0165	0.0215	CbGbCtD
Dapagliflozin—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0158	0.0206	CbGbCtD
Dapagliflozin—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0156	0.0203	CbGbCtD
Dapagliflozin—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0156	0.0203	CbGbCtD
Dapagliflozin—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0147	0.0191	CbGbCtD
Dapagliflozin—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0143	0.0186	CbGbCtD
Dapagliflozin—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0143	0.0186	CbGbCtD
Dapagliflozin—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0143	0.0186	CbGbCtD
Dapagliflozin—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0138	0.018	CbGbCtD
Dapagliflozin—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0134	0.0175	CbGbCtD
Dapagliflozin—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.013	0.017	CbGbCtD
Dapagliflozin—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0129	0.0168	CbGbCtD
Dapagliflozin—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0129	0.0168	CbGbCtD
Dapagliflozin—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0125	0.0163	CbGbCtD
Dapagliflozin—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0125	0.0163	CbGbCtD
Dapagliflozin—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0124	0.0161	CbGbCtD
Dapagliflozin—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.012	0.0156	CbGbCtD
Dapagliflozin—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0118	0.0154	CbGbCtD
Dapagliflozin—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0118	0.0154	CbGbCtD
Dapagliflozin—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0116	0.0152	CbGbCtD
Dapagliflozin—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0109	0.0143	CbGbCtD
Dapagliflozin—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0109	0.0143	CbGbCtD
Dapagliflozin—SLC5A4—blood plasma—acquired immunodeficiency syndrome	0.0101	0.134	CbGeAlD
Dapagliflozin—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0099	0.0129	CbGbCtD
Dapagliflozin—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0099	0.0129	CbGbCtD
Dapagliflozin—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00928	0.0121	CbGbCtD
Dapagliflozin—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00854	0.0111	CbGbCtD
Dapagliflozin—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00829	0.0108	CbGbCtD
Dapagliflozin—SLC5A2—blood plasma—acquired immunodeficiency syndrome	0.00769	0.101	CbGeAlD
Dapagliflozin—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0075	0.00977	CbGbCtD
Dapagliflozin—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0075	0.00977	CbGbCtD
Dapagliflozin—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00719	0.00936	CbGbCtD
Dapagliflozin—SLC5A4—digestive system—acquired immunodeficiency syndrome	0.0039	0.0514	CbGeAlD
Dapagliflozin—SLC5A11—blood—acquired immunodeficiency syndrome	0.00338	0.0445	CbGeAlD
Dapagliflozin—SLC5A11—spinal cord—acquired immunodeficiency syndrome	0.00325	0.0428	CbGeAlD
Dapagliflozin—SLC5A4—nervous system—acquired immunodeficiency syndrome	0.00302	0.0397	CbGeAlD
Dapagliflozin—SLC5A4—central nervous system—acquired immunodeficiency syndrome	0.00291	0.0383	CbGeAlD
Dapagliflozin—SLC5A2—blood—acquired immunodeficiency syndrome	0.00282	0.0371	CbGeAlD
Dapagliflozin—SLC5A11—nervous system—acquired immunodeficiency syndrome	0.00274	0.0361	CbGeAlD
Dapagliflozin—Canagliflozin—ALB—acquired immunodeficiency syndrome	0.00274	1	CrCbGaD
Dapagliflozin—SLC5A11—central nervous system—acquired immunodeficiency syndrome	0.00264	0.0348	CbGeAlD
Dapagliflozin—SLC5A2—vagina—acquired immunodeficiency syndrome	0.00261	0.0344	CbGeAlD
Dapagliflozin—SLC5A4—brain—acquired immunodeficiency syndrome	0.00231	0.0304	CbGeAlD
Dapagliflozin—SLC5A1—digestive system—acquired immunodeficiency syndrome	0.00224	0.0295	CbGeAlD
Dapagliflozin—SLC5A11—brain—acquired immunodeficiency syndrome	0.00209	0.0276	CbGeAlD
Dapagliflozin—SLC5A1—vagina—acquired immunodeficiency syndrome	0.00198	0.0261	CbGeAlD
Dapagliflozin—SLC5A1—lung—acquired immunodeficiency syndrome	0.00187	0.0247	CbGeAlD
Dapagliflozin—UGT2B4—lung—acquired immunodeficiency syndrome	0.00172	0.0227	CbGeAlD
Dapagliflozin—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.00141	0.0186	CbGeAlD
Dapagliflozin—UGT2B7—digestive system—acquired immunodeficiency syndrome	0.00114	0.015	CbGeAlD
Dapagliflozin—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00111	0.0147	CbGeAlD
Dapagliflozin—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00106	0.0139	CbGeAlD
Dapagliflozin—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000806	0.0106	CbGeAlD
Dapagliflozin—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000793	0.0104	CbGeAlD
Dapagliflozin—CYP2A6—vagina—acquired immunodeficiency syndrome	0.00072	0.00948	CbGeAlD
Dapagliflozin—CYP2A6—lung—acquired immunodeficiency syndrome	0.000681	0.00896	CbGeAlD
Dapagliflozin—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00057	0.00751	CbGeAlD
Dapagliflozin—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000528	0.00695	CbGeAlD
Dapagliflozin—Malnutrition—Nelfinavir—acquired immunodeficiency syndrome	0.000512	0.00334	CcSEcCtD
Dapagliflozin—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.000511	0.00333	CcSEcCtD
Dapagliflozin—Malnutrition—Stavudine—acquired immunodeficiency syndrome	0.00051	0.00333	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Zidovudine—acquired immunodeficiency syndrome	0.000503	0.00328	CcSEcCtD
Dapagliflozin—Malnutrition—Abacavir—acquired immunodeficiency syndrome	0.000503	0.00328	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Zidovudine—acquired immunodeficiency syndrome	0.000501	0.00326	CcSEcCtD
Dapagliflozin—Urethral disorder—Zidovudine—acquired immunodeficiency syndrome	0.000499	0.00326	CcSEcCtD
Dapagliflozin—Infestation NOS—Efavirenz—acquired immunodeficiency syndrome	0.000499	0.00325	CcSEcCtD
Dapagliflozin—Infestation—Efavirenz—acquired immunodeficiency syndrome	0.000499	0.00325	CcSEcCtD
Dapagliflozin—Back pain—Nelfinavir—acquired immunodeficiency syndrome	0.000495	0.00323	CcSEcCtD
Dapagliflozin—Influenza—Ritonavir—acquired immunodeficiency syndrome	0.000495	0.00323	CcSEcCtD
Dapagliflozin—Discomfort—Didanosine—acquired immunodeficiency syndrome	0.000494	0.00322	CcSEcCtD
Dapagliflozin—Back pain—Stavudine—acquired immunodeficiency syndrome	0.000494	0.00322	CcSEcCtD
Dapagliflozin—Renal failure—Efavirenz—acquired immunodeficiency syndrome	0.00049	0.0032	CcSEcCtD
Dapagliflozin—Dehydration—Lamivudine—acquired immunodeficiency syndrome	0.000489	0.00319	CcSEcCtD
Dapagliflozin—Angioedema—Nevirapine—acquired immunodeficiency syndrome	0.000483	0.00315	CcSEcCtD
Dapagliflozin—CYP2A6—brain—acquired immunodeficiency syndrome	0.000482	0.00634	CbGeAlD
Dapagliflozin—Anaphylactic shock—Didanosine—acquired immunodeficiency syndrome	0.00048	0.00313	CcSEcCtD
Dapagliflozin—Infection—Didanosine—acquired immunodeficiency syndrome	0.000477	0.00311	CcSEcCtD
Dapagliflozin—Influenza—Saquinavir—acquired immunodeficiency syndrome	0.000476	0.0031	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.00047	0.00306	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Indinavir—acquired immunodeficiency syndrome	0.000468	0.00305	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Indinavir—acquired immunodeficiency syndrome	0.000466	0.00303	CcSEcCtD
Dapagliflozin—Urethral disorder—Indinavir—acquired immunodeficiency syndrome	0.000465	0.00303	CcSEcCtD
Dapagliflozin—Urinary tract infection—Delavirdine—acquired immunodeficiency syndrome	0.000464	0.00302	CcSEcCtD
Dapagliflozin—Dysuria—Ritonavir—acquired immunodeficiency syndrome	0.000463	0.00302	CcSEcCtD
Dapagliflozin—Pollakiuria—Ritonavir—acquired immunodeficiency syndrome	0.000457	0.00298	CcSEcCtD
Dapagliflozin—Influenza—Lamivudine—acquired immunodeficiency syndrome	0.000454	0.00296	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.000454	0.00296	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.000447	0.00291	CcSEcCtD
Dapagliflozin—Discomfort—Nevirapine—acquired immunodeficiency syndrome	0.000445	0.0029	CcSEcCtD
Dapagliflozin—Malnutrition—Zidovudine—acquired immunodeficiency syndrome	0.000444	0.00289	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Efavirenz—acquired immunodeficiency syndrome	0.000442	0.00288	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Efavirenz—acquired immunodeficiency syndrome	0.00044	0.00287	CcSEcCtD
Dapagliflozin—Urethral disorder—Efavirenz—acquired immunodeficiency syndrome	0.000439	0.00286	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Ritonavir—acquired immunodeficiency syndrome	0.000435	0.00284	CcSEcCtD
Dapagliflozin—Renal failure—Ritonavir—acquired immunodeficiency syndrome	0.000434	0.00283	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.000433	0.00282	CcSEcCtD
Dapagliflozin—Myocardial infarction—Ritonavir—acquired immunodeficiency syndrome	0.000433	0.00282	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.000431	0.00281	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Nevirapine—acquired immunodeficiency syndrome	0.000431	0.00281	CcSEcCtD
Dapagliflozin—Oedema—Nevirapine—acquired immunodeficiency syndrome	0.000431	0.00281	CcSEcCtD
Dapagliflozin—Discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.000431	0.00281	CcSEcCtD
Dapagliflozin—Back pain—Zidovudine—acquired immunodeficiency syndrome	0.000429	0.0028	CcSEcCtD
Dapagliflozin—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.000429	0.0028	CcSEcCtD
Dapagliflozin—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000428	0.00564	CbGeAlD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.000425	0.00277	CcSEcCtD
Dapagliflozin—Dysuria—Lamivudine—acquired immunodeficiency syndrome	0.000425	0.00277	CcSEcCtD
Dapagliflozin—Infestation NOS—Saquinavir—acquired immunodeficiency syndrome	0.000425	0.00277	CcSEcCtD
Dapagliflozin—Infestation—Saquinavir—acquired immunodeficiency syndrome	0.000425	0.00277	CcSEcCtD
Dapagliflozin—Discomfort—Abacavir—acquired immunodeficiency syndrome	0.000423	0.00276	CcSEcCtD
Dapagliflozin—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000422	0.00556	CbGeAlD
Dapagliflozin—Pollakiuria—Lamivudine—acquired immunodeficiency syndrome	0.00042	0.00274	CcSEcCtD
Dapagliflozin—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.000419	0.00273	CcSEcCtD
Dapagliflozin—Oedema—Nelfinavir—acquired immunodeficiency syndrome	0.000418	0.00272	CcSEcCtD
Dapagliflozin—Renal failure—Saquinavir—acquired immunodeficiency syndrome	0.000418	0.00272	CcSEcCtD
Dapagliflozin—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.000413	0.00269	CcSEcCtD
Dapagliflozin—Malnutrition—Indinavir—acquired immunodeficiency syndrome	0.000413	0.00269	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Abacavir—acquired immunodeficiency syndrome	0.00041	0.00267	CcSEcCtD
Dapagliflozin—Oedema—Abacavir—acquired immunodeficiency syndrome	0.00041	0.00267	CcSEcCtD
Dapagliflozin—CYP1A2—blood—acquired immunodeficiency syndrome	0.000408	0.00537	CbGeAlD
Dapagliflozin—Infection—Abacavir—acquired immunodeficiency syndrome	0.000408	0.00266	CcSEcCtD
Dapagliflozin—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000406	0.00535	CbGeAlD
Dapagliflozin—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000406	0.00264	CcSEcCtD
Dapagliflozin—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.000405	0.00264	CcSEcCtD
Dapagliflozin—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.000405	0.00264	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Nelfinavir—acquired immunodeficiency syndrome	0.000404	0.00263	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Stavudine—acquired immunodeficiency syndrome	0.000403	0.00262	CcSEcCtD
Dapagliflozin—CYP1A1—blood—acquired immunodeficiency syndrome	0.000402	0.0053	CbGeAlD
Dapagliflozin—Back pain—Indinavir—acquired immunodeficiency syndrome	0.000399	0.0026	CcSEcCtD
Dapagliflozin—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000399	0.0026	CcSEcCtD
Dapagliflozin—Renal failure—Lamivudine—acquired immunodeficiency syndrome	0.000398	0.0026	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Ritonavir—acquired immunodeficiency syndrome	0.000391	0.00255	CcSEcCtD
Dapagliflozin—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.00039	0.00254	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Ritonavir—acquired immunodeficiency syndrome	0.000389	0.00254	CcSEcCtD
Dapagliflozin—Urethral disorder—Ritonavir—acquired immunodeficiency syndrome	0.000388	0.00253	CcSEcCtD
Dapagliflozin—CYP2C9—blood—acquired immunodeficiency syndrome	0.000387	0.0051	CbGeAlD
Dapagliflozin—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.000383	0.0025	CcSEcCtD
Dapagliflozin—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000379	0.00247	CcSEcCtD
Dapagliflozin—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.000377	0.00246	CcSEcCtD
Dapagliflozin—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.000377	0.00246	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.000377	0.00245	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000375	0.00244	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.000375	0.00244	CcSEcCtD
Dapagliflozin—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.000374	0.00244	CcSEcCtD
Dapagliflozin—Discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000373	0.00243	CcSEcCtD
Dapagliflozin—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000373	0.00243	CcSEcCtD
Dapagliflozin—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000373	0.00491	CbGeAlD
Dapagliflozin—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000372	0.00243	CcSEcCtD
Dapagliflozin—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000362	0.00236	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000362	0.00236	CcSEcCtD
Dapagliflozin—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.000361	0.00235	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000361	0.00235	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.00036	0.00234	CcSEcCtD
Dapagliflozin—CYP1A2—lung—acquired immunodeficiency syndrome	0.000357	0.00471	CbGeAlD
Dapagliflozin—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.000357	0.00233	CcSEcCtD
Dapagliflozin—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000356	0.00232	CcSEcCtD
Dapagliflozin—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.000356	0.00232	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000354	0.00231	CcSEcCtD
Dapagliflozin—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000353	0.0023	CcSEcCtD
Dapagliflozin—CYP1A1—lung—acquired immunodeficiency syndrome	0.000353	0.00464	CbGeAlD
Dapagliflozin—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000352	0.00229	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.00035	0.00228	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000349	0.00227	CcSEcCtD
Dapagliflozin—Discomfort—Indinavir—acquired immunodeficiency syndrome	0.000347	0.00226	CcSEcCtD
Dapagliflozin—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000345	0.00225	CcSEcCtD
Dapagliflozin—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000343	0.00223	CcSEcCtD
Dapagliflozin—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000341	0.00222	CcSEcCtD
Dapagliflozin—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000341	0.00222	CcSEcCtD
Dapagliflozin—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000337	0.00219	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000337	0.00219	CcSEcCtD
Dapagliflozin—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000336	0.00219	CcSEcCtD
Dapagliflozin—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000334	0.00217	CcSEcCtD
Dapagliflozin—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000332	0.00216	CcSEcCtD
Dapagliflozin—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000332	0.00216	CcSEcCtD
Dapagliflozin—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000332	0.00216	CcSEcCtD
Dapagliflozin—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000331	0.00216	CcSEcCtD
Dapagliflozin—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000331	0.00216	CcSEcCtD
Dapagliflozin—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.00033	0.00215	CcSEcCtD
Dapagliflozin—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00033	0.00215	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00033	0.00215	CcSEcCtD
Dapagliflozin—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000329	0.00215	CcSEcCtD
Dapagliflozin—Discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000328	0.00214	CcSEcCtD
Dapagliflozin—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000327	0.00213	CcSEcCtD
Dapagliflozin—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000327	0.0043	CbGeAlD
Dapagliflozin—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000326	0.00212	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000325	0.00212	CcSEcCtD
Dapagliflozin—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000324	0.00211	CcSEcCtD
Dapagliflozin—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000322	0.0021	CcSEcCtD
Dapagliflozin—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000321	0.00209	CcSEcCtD
Dapagliflozin—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000318	0.00207	CcSEcCtD
Dapagliflozin—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000317	0.00206	CcSEcCtD
Dapagliflozin—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000314	0.00414	CbGeAlD
Dapagliflozin—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000314	0.00204	CcSEcCtD
Dapagliflozin—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000313	0.00204	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000313	0.00204	CcSEcCtD
Dapagliflozin—ABCB1—retina—acquired immunodeficiency syndrome	0.000312	0.00411	CbGeAlD
Dapagliflozin—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.00031	0.00408	CbGeAlD
Dapagliflozin—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00031	0.00202	CcSEcCtD
Dapagliflozin—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000309	0.00201	CcSEcCtD
Dapagliflozin—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000308	0.00201	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000307	0.002	CcSEcCtD
Dapagliflozin—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000307	0.002	CcSEcCtD
Dapagliflozin—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000306	0.002	CcSEcCtD
Dapagliflozin—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000305	0.00402	CbGeAlD
Dapagliflozin—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000304	0.00198	CcSEcCtD
Dapagliflozin—Rash—Didanosine—acquired immunodeficiency syndrome	0.000302	0.00197	CcSEcCtD
Dapagliflozin—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000302	0.00197	CcSEcCtD
Dapagliflozin—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000302	0.00197	CcSEcCtD
Dapagliflozin—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000302	0.00197	CcSEcCtD
Dapagliflozin—Headache—Didanosine—acquired immunodeficiency syndrome	0.000301	0.00196	CcSEcCtD
Dapagliflozin—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000298	0.00194	CcSEcCtD
Dapagliflozin—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000296	0.00193	CcSEcCtD
Dapagliflozin—CYP3A4—blood—acquired immunodeficiency syndrome	0.000295	0.00389	CbGeAlD
Dapagliflozin—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000294	0.00192	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.0019	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000291	0.00189	CcSEcCtD
Dapagliflozin—CYP2D6—blood—acquired immunodeficiency syndrome	0.00029	0.00383	CbGeAlD
Dapagliflozin—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00029	0.00189	CcSEcCtD
Dapagliflozin—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000289	0.00189	CcSEcCtD
Dapagliflozin—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000288	0.00188	CcSEcCtD
Dapagliflozin—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000288	0.00187	CcSEcCtD
Dapagliflozin—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000287	0.00187	CcSEcCtD
Dapagliflozin—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000286	0.00187	CcSEcCtD
Dapagliflozin—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000285	0.00186	CcSEcCtD
Dapagliflozin—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000284	0.00185	CcSEcCtD
Dapagliflozin—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000281	0.00183	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.00183	CcSEcCtD
Dapagliflozin—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.00182	CcSEcCtD
Dapagliflozin—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000276	0.0018	CcSEcCtD
Dapagliflozin—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000275	0.0018	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000275	0.00179	CcSEcCtD
Dapagliflozin—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00178	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.00177	CcSEcCtD
Dapagliflozin—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000272	0.00177	CcSEcCtD
Dapagliflozin—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000272	0.00177	CcSEcCtD
Dapagliflozin—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000272	0.00177	CcSEcCtD
Dapagliflozin—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000271	0.00177	CcSEcCtD
Dapagliflozin—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000271	0.00177	CcSEcCtD
Dapagliflozin—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00027	0.00176	CcSEcCtD
Dapagliflozin—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000269	0.00175	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.00174	CcSEcCtD
Dapagliflozin—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00174	CcSEcCtD
Dapagliflozin—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000266	0.00174	CcSEcCtD
Dapagliflozin—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000266	0.00173	CcSEcCtD
Dapagliflozin—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000263	0.00172	CcSEcCtD
Dapagliflozin—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000263	0.00172	CcSEcCtD
Dapagliflozin—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.00171	CcSEcCtD
Dapagliflozin—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000263	0.00171	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000263	0.00171	CcSEcCtD
Dapagliflozin—Rash—Stavudine—acquired immunodeficiency syndrome	0.000263	0.00171	CcSEcCtD
Dapagliflozin—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000262	0.00171	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.00171	CcSEcCtD
Dapagliflozin—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000262	0.00171	CcSEcCtD
Dapagliflozin—Headache—Stavudine—acquired immunodeficiency syndrome	0.000261	0.0017	CcSEcCtD
Dapagliflozin—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00026	0.0017	CcSEcCtD
Dapagliflozin—Rash—Abacavir—acquired immunodeficiency syndrome	0.000259	0.00169	CcSEcCtD
Dapagliflozin—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000258	0.00168	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000258	0.00168	CcSEcCtD
Dapagliflozin—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000258	0.00168	CcSEcCtD
Dapagliflozin—Headache—Abacavir—acquired immunodeficiency syndrome	0.000257	0.00168	CcSEcCtD
Dapagliflozin—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000257	0.00167	CcSEcCtD
Dapagliflozin—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000256	0.00167	CcSEcCtD
Dapagliflozin—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000253	0.00165	CcSEcCtD
Dapagliflozin—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000253	0.00165	CcSEcCtD
Dapagliflozin—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000251	0.00164	CcSEcCtD
Dapagliflozin—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.00164	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00163	CcSEcCtD
Dapagliflozin—CYP1A1—brain—acquired immunodeficiency syndrome	0.00025	0.00329	CbGeAlD
Dapagliflozin—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000248	0.00162	CcSEcCtD
Dapagliflozin—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000248	0.00162	CcSEcCtD
Dapagliflozin—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000247	0.00161	CcSEcCtD
Dapagliflozin—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000244	0.00159	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.00158	CcSEcCtD
Dapagliflozin—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000242	0.00158	CcSEcCtD
Dapagliflozin—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000241	0.00157	CcSEcCtD
Dapagliflozin—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000241	0.00318	CbGeAlD
Dapagliflozin—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000241	0.00157	CcSEcCtD
Dapagliflozin—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.00157	CcSEcCtD
Dapagliflozin—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.00024	0.00316	CbGeAlD
Dapagliflozin—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000239	0.00156	CcSEcCtD
Dapagliflozin—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000236	0.00311	CbGeAlD
Dapagliflozin—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000234	0.00153	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.00152	CcSEcCtD
Dapagliflozin—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.00151	CcSEcCtD
Dapagliflozin—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000231	0.00304	CbGeAlD
Dapagliflozin—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000228	0.00149	CcSEcCtD
Dapagliflozin—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000228	0.00149	CcSEcCtD
Dapagliflozin—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000227	0.00299	CbGeAlD
Dapagliflozin—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000227	0.00148	CcSEcCtD
Dapagliflozin—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.00146	CcSEcCtD
Dapagliflozin—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.00146	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.00145	CcSEcCtD
Dapagliflozin—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000223	0.00145	CcSEcCtD
Dapagliflozin—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000222	0.00145	CcSEcCtD
Dapagliflozin—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000222	0.00292	CbGeAlD
Dapagliflozin—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000221	0.00144	CcSEcCtD
Dapagliflozin—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000219	0.00289	CbGeAlD
Dapagliflozin—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.0014	CcSEcCtD
Dapagliflozin—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000215	0.0014	CcSEcCtD
Dapagliflozin—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000214	0.0014	CcSEcCtD
Dapagliflozin—Rash—Indinavir—acquired immunodeficiency syndrome	0.000212	0.00138	CcSEcCtD
Dapagliflozin—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000212	0.00138	CcSEcCtD
Dapagliflozin—Headache—Indinavir—acquired immunodeficiency syndrome	0.000211	0.00137	CcSEcCtD
Dapagliflozin—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00021	0.00137	CcSEcCtD
Dapagliflozin—ABCB1—blood—acquired immunodeficiency syndrome	0.000209	0.00275	CbGeAlD
Dapagliflozin—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.00135	CcSEcCtD
Dapagliflozin—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.00134	CcSEcCtD
Dapagliflozin—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.00133	CcSEcCtD
Dapagliflozin—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000202	0.00266	CbGeAlD
Dapagliflozin—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000201	0.00265	CbGeAlD
Dapagliflozin—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000201	0.00131	CcSEcCtD
Dapagliflozin—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000201	0.00131	CcSEcCtD
Dapagliflozin—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.0002	0.00131	CcSEcCtD
Dapagliflozin—Nausea—Indinavir—acquired immunodeficiency syndrome	0.0002	0.0013	CcSEcCtD
Dapagliflozin—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.0013	CcSEcCtD
Dapagliflozin—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000199	0.0013	CcSEcCtD
Dapagliflozin—ABCB1—vagina—acquired immunodeficiency syndrome	0.000194	0.00255	CbGeAlD
Dapagliflozin—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000192	0.00125	CcSEcCtD
Dapagliflozin—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000192	0.00125	CcSEcCtD
Dapagliflozin—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000191	0.00124	CcSEcCtD
Dapagliflozin—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.00124	CcSEcCtD
Dapagliflozin—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000189	0.00123	CcSEcCtD
Dapagliflozin—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000186	0.00121	CcSEcCtD
Dapagliflozin—ABCB1—lung—acquired immunodeficiency syndrome	0.000183	0.00241	CbGeAlD
Dapagliflozin—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000181	0.00118	CcSEcCtD
Dapagliflozin—CYP2D6—brain—acquired immunodeficiency syndrome	0.00018	0.00237	CbGeAlD
Dapagliflozin—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000179	0.00117	CcSEcCtD
Dapagliflozin—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000177	0.00116	CcSEcCtD
Dapagliflozin—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000177	0.00116	CcSEcCtD
Dapagliflozin—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.00115	CcSEcCtD
Dapagliflozin—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000171	0.00111	CcSEcCtD
Dapagliflozin—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000171	0.00111	CcSEcCtD
Dapagliflozin—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000171	0.00111	CcSEcCtD
Dapagliflozin—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00017	0.00111	CcSEcCtD
Dapagliflozin—ABCB1—nervous system—acquired immunodeficiency syndrome	0.00017	0.00223	CbGeAlD
Dapagliflozin—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000167	0.00109	CcSEcCtD
Dapagliflozin—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000163	0.00215	CbGeAlD
Dapagliflozin—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000163	0.00106	CcSEcCtD
Dapagliflozin—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000163	0.00106	CcSEcCtD
Dapagliflozin—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.00106	CcSEcCtD
Dapagliflozin—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000161	0.00105	CcSEcCtD
Dapagliflozin—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000153	0.001	CcSEcCtD
Dapagliflozin—ABCB1—brain—acquired immunodeficiency syndrome	0.00013	0.00171	CbGeAlD
Dapagliflozin—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000125	0.00165	CbGeAlD
